BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pantziarka P, Hutchinson L, André N, Benzekry S, Bertolini F, Bhattacharjee A, Chiplunkar S, Duda DG, Gota V, Gupta S, Joshi A, Kannan S, Kerbel R, Kieran M, Palazzo A, Parikh A, Pasquier E, Patil V, Prabhash K, Shaked Y, Sholler GS, Sterba J, Waxman DJ, Banavali S. Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai. Ecancermedicalscience 2016;10:689. [PMID: 27994645 DOI: 10.3332/ecancer.2016.689] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 André N, Tsai K, Carré M, Pasquier E. Metronomic Chemotherapy: Direct Targeting of Cancer Cells after all? Trends in Cancer 2017;3:319-25. [DOI: 10.1016/j.trecan.2017.03.011] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 7.2] [Reference Citation Analysis]
2 El Kababri M, Benmiloud S, Cherkaoui S, El Houdzi J, Maani K, Ansari N, Khoubila N, Kili A, El Khorassani M, Madani A, Tazi MA, Ahid S, Hessissen L, Quessar A, Harif M, Khattab M, André N. Metro-SMHOP 01: Metronomics combination with cyclophosphamide-etoposide and valproic acid for refractory and relapsing pediatric malignancies. Pediatr Blood Cancer 2020;67:e28508. [PMID: 32658380 DOI: 10.1002/pbc.28508] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Pramanik R, Bakhshi S. Metronomic therapy in pediatric oncology: A snapshot. Pediatr Blood Cancer 2019;66. [DOI: 10.1002/pbc.27811] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
4 Boyer A, Pasquier E, Tomasini P, Ciccolini J, Greillier L, Andre N, Barlesi F, Mascaux C. Drug repurposing in malignant pleural mesothelioma: a breath of fresh air? Eur Respir Rev 2018;27:170098. [PMID: 29540495 DOI: 10.1183/16000617.0098-2017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
5 Lambrescu I, Fica S, Martins D, Spada F, Cella C, Bertani E, Rubino M, Gibelli B, Grana C, Bonomo G, Funicelli L, Ravizza D, Pisa E, Zerini D, Ungaro A, Fazio N; IEO ENETS Center of Excellence for GEP NET. Metronomic and metronomic-like therapies in neuroendocrine tumors - Rationale and clinical perspectives. Cancer Treat Rev 2017;55:46-56. [PMID: 28314176 DOI: 10.1016/j.ctrv.2017.02.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
6 Yanwei L, Yinli Y, Pan Z. Traditional Herbal Formula NPC01 Exerts Antiangiogenic Effects through Inhibiting the PI3K/Akt/mTOR Signaling Pathway in Nasopharyngeal Carcinoma Cells. Evid Based Complement Alternat Med 2018;2018:5291517. [PMID: 29636781 DOI: 10.1155/2018/5291517] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
7 Bhattacharjee A, Patil VM, Noronha V, Joshi A, Prabhash K. An Algorithm to Define the Optimum Biological Dose of Metronomic Chemotherapy. Biometrical Letters 2018;55:1-15. [DOI: 10.2478/bile-2018-0001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Wu J, Waxman DJ. Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy. Cancer Lett 2018;419:210-21. [PMID: 29414305 DOI: 10.1016/j.canlet.2018.01.050] [Cited by in Crossref: 98] [Cited by in F6Publishing: 93] [Article Influence: 32.7] [Reference Citation Analysis]